{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:12:47Z","timestamp":1793301167564,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00787-024-02623-3","type":"journal-article","created":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T23:50:00Z","timestamp":1733097000000},"page":"2083-2091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-905X","authenticated-orcid":false,"given":"Carlos","family":"De las Cuevas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-4435","authenticated-orcid":false,"given":"Emilio J.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1515-2413","authenticated-orcid":false,"given":"Sara","family":"Jim\u00e9nez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1625-7367","authenticated-orcid":false,"given":"Can-Jun","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2314","authenticated-orcid":false,"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"2623_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000507638","volume":"89","author":"J de Leon","year":"2020","unstructured":"de Leon J, Ruan CJ, Schoretsanitis G, De Las Cuevas C (2020) A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom 89:200\u2013214. https:\/\/doi.org\/10.1159\/000507638","journal-title":"Psychother Psychosom"},{"key":"2623_CR2","unstructured":"Therapeutics HLS (2023) Inc., CLOZARIL- clozapine tablet. HLS Therapeutics (USA), Inc.Rosemont, PA. Revised in May 2023. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=90876802-0e3a-44c9-9ff7-1754dfbe736a (accessed 30 June, 2023)"},{"key":"2623_CR3","doi-asserted-by":"publisher","unstructured":"Meltzer HY, Alphs L, Green AI et a. Clozapine treatment for suicidality in schizophrenia: international suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82\u201391. https:\/\/doi.org\/10.1001\/archpsyc.60.1.82","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"2623_CR4","doi-asserted-by":"publisher","unstructured":"De Las Cuevas C, Sanz EJ, de Leon J (2024) Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: comparing the top four reporting countries (US, UK, Canada and Australia). Schizophr Res 268:165\u2013174 https:\/\/doi.org\/10.2147\/PPA.S495254","DOI":"10.2147\/PPA.S495254"},{"key":"2623_CR5","doi-asserted-by":"publisher","unstructured":"De Las Cuevas C, de Leon VC, Blasco-Fontecilla H et al (2024) Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature. Expert Opin Drug Saf 2024 Sep 11:1\u201311. Epub ahead of print. PMID: 39223773. https:\/\/doi.org\/10.1080\/14740338.2024.2399094","DOI":"10.1080\/14740338.2024.2399094"},{"key":"2623_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/acps.13267","volume":"143","author":"Y van der Zalm","year":"2021","unstructured":"van der Zalm Y, Foldager L, Termorshuizen F, Sommer IE, Nielsen J, Selten JP (2021) Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study. Acta Psychiatr Scand 143:216\u2013226. https:\/\/doi.org\/10.1111\/acps.13267","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"2623_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wps.20699","volume":"19","author":"H Taipale","year":"2020","unstructured":"Taipale H, Tanskanen A, Meht\u00e4l\u00e4 J, Vattulainen P, Correll CU, Tiihonen J (2020) 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 19(1):61\u201368. https:\/\/doi.org\/10.1002\/wps.20699","journal-title":"World Psychiatry"},{"key":"2623_CR8","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","volume":"174","author":"T Wimberley","year":"2017","unstructured":"Wimberley T, MacCabe JH, Laursen TM et al (2017) Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174:990\u2013998. https:\/\/doi.org\/10.1176\/appi.ajp.2017.16091097","journal-title":"Am J Psychiatry"},{"key":"2623_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/schbul\/sbaa111","volume":"47","author":"H Taipale","year":"2021","unstructured":"Taipale H, L\u00e4hteenvuo M, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J (2021) Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia. Schizophr Bull 47:23\u201330. https:\/\/doi.org\/10.1093\/schbul\/sbaa111","journal-title":"Schizophr Bull"},{"key":"2623_CR10","doi-asserted-by":"publisher","unstructured":"Chen W-Y, Chen P-H, Pan H-C et al (2024) Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: a nationwide cohort study in Taiwan. Schizophr Res 2024;268:150\u2013160. https:\/\/doi.org\/10.1016\/j.schres.2023.07.014","DOI":"10.1016\/j.schres.2023.07.014"},{"key":"2623_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.schres.2004.05.015","volume":"73","author":"J Hennen","year":"2005","unstructured":"Hennen J, Baldessarini RJ (2005) Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 73:139\u2013145. https:\/\/doi.org\/10.1016\/j.schres.2004.05.015","journal-title":"Schizophr Res"},{"key":"2623_CR12","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/02698811211029738","volume":"35","author":"A Forte","year":"2021","unstructured":"Forte A, Pompili M, Imbastaro B et al (2021) Effects on suicidal risk: comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. J Psychopharmacol 35:1074\u20131080. https:\/\/doi.org\/10.1177\/02698811211029738","journal-title":"J Psychopharmacol"},{"key":"2623_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.euroneuro.2022.12.011","volume":"69","author":"VG Masdrakis","year":"2023","unstructured":"Masdrakis VG, Baldwin DS (2023) Prevention of suicide by clozapine in mental disorders: systematic review. Eur Neuropsychopharmacol 69:4\u201323. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.12.011","journal-title":"Eur Neuropsychopharmacol"},{"key":"2623_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/da.23222","volume":"39","author":"ST Wilkinson","year":"2022","unstructured":"Wilkinson ST, Trujillo Diaz D, Rupp ZW et al (2022) Pharmacological and somatic treatment effects on suicide in adults: a systematic review and meta-analysis. Depress Anxiety 39:100\u2013112. https:\/\/doi.org\/10.1002\/da.23222","journal-title":"Depress Anxiety"},{"key":"2623_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12888-018-1993-3","volume":"18","author":"AE Ferrey","year":"2018","unstructured":"Ferrey AE, Geulayov G, Casey D et al (2018) Relative toxicity of mood stabilisers and antipsychotics: case fatality and fatal toxicity associated with self- poisoning. BMC Psychiatry 18:399. https:\/\/doi.org\/10.1186\/s12888-018-1993-3","journal-title":"BMC Psychiatry"},{"key":"2623_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bdi.12018","volume":"14","author":"J Nielsen","year":"2012","unstructured":"Nielsen J, Kane JM, Correll CU (2012) Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord 14:863\u2013869. https:\/\/doi.org\/10.1111\/bdi.12018","journal-title":"Bipolar Disord"},{"key":"2623_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bdi.12272","volume":"17","author":"XB Li","year":"2015","unstructured":"Li XB, Tang YL, Wang CY, de Leon J (2015) Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord 17:235\u2013247. https:\/\/doi.org\/10.1111\/bdi.12272","journal-title":"Bipolar Disord"},{"key":"2623_CR18","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00213-023-06431-6","volume":"240","author":"J Han","year":"2023","unstructured":"Han J, Allison S, Looi JCL, Chan SKW, Bastiampillai T (2023) A systematic review of the role of clozapine for severe borderline personality disorder. Psychopharmacology 240:2015\u20132031. https:\/\/doi.org\/10.1007\/s00213-023-06431-6","journal-title":"Psychopharmacology"},{"key":"2623_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/schbul\/sbz093","volume":"46","author":"J De Leon","year":"2020","unstructured":"De Leon J, Sanz EJ, De Las Cuevas C (2020) Data from the World Health Organization\u2019s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull 46:1\u20133. https:\/\/doi.org\/10.1093\/schbul\/sbz093","journal-title":"Schizophr Bull"},{"key":"2623_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.schres.2023.11.010","volume":"268","author":"C De Las Cuevas","year":"2024","unstructured":"De Las Cuevas C, Sanz EJ et al (2024) Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other western European countries compared to the UK. Schizophr Res 268:175\u2013188. https:\/\/doi.org\/10.1016\/j.schres.2023.11.010","journal-title":"Schizophr Res"},{"key":"2623_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.schres.2023.09.002","volume":"268","author":"M Sagud","year":"2024","unstructured":"Sagud M, Breznoscakova D, Celofiga A et al (2024) An expert review of clozapine in eastern European countries: use, regulations and pharmacovigilance. Schizophr Res 268:53\u201359. https:\/\/doi.org\/10.1016\/j.schres.2023.09.002","journal-title":"Schizophr Res"},{"key":"2623_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.schres.2023.10.025","volume":"268","author":"T Baptista","year":"2024","unstructured":"Baptista T, Motuca M, Serrano A et al (2024) An expert review of clozapine in Latin America countries: use, monitoring, and pharmacovigilance. Schizophr Res 268:60\u201365. https:\/\/doi.org\/10.1016\/j.schres.2023.10.025","journal-title":"Schizophr Res"},{"key":"2623_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.rpsmen.2021.07.005","volume":"15","author":"C De Las Cuevas","year":"2022","unstructured":"De Las Cuevas C, Sanz EJ, Ruan CJ, de Leon J (2022) Clozapine-associated myocarditis in the World Health Organization\u2019s pharmacovigilance database: focus on reports from various countries. Rev Psiquiatr Salud Ment (Engl Ed) 15:238\u2013250. https:\/\/doi.org\/10.1016\/j.rpsmen.2021.07.005","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)"},{"key":"2623_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.9758\/cpn.2019.17.1.43","volume":"17","author":"M Ju\u00e1rez-Trevi\u00f1o","year":"2019","unstructured":"Ju\u00e1rez-Trevi\u00f1o M, Esquivel AC, Isida LML et al (2019) Clozapine in the treatment of aggression in conduct disorder in children and adolescents: a randomized, double-blind, controlled trial. Clin Psychopharmacol Neurosci 17:43\u201353. https:\/\/doi.org\/10.9758\/cpn.2019.17.1.43","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2623_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","volume":"28","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M et al (2018) Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol 28:659\u2013674. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.008","journal-title":"Eur Neuropsychopharmacol"},{"key":"2623_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaac.2023.10.016","volume":"63","author":"G Salazar de Pablo","year":"2024","unstructured":"Salazar de Pablo G, Rodriguez V, Besana F et al (2024) Umbrella review: atlas of the meta-analytical evidence of early-onset psychosis. J Am Acad Child Adolesc Psychiatry 63:684\u2013697. https:\/\/doi.org\/10.1016\/j.jaac.2023.10.016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2623_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.euroneuro.2024.02.005","volume":"82","author":"CU Correll","year":"2024","unstructured":"Correll CU, Arango C, Fagerlund B, Galderisi S, Kas MJ, Leucht S (2024) Identification and treatment of individuals with childhood-onset and early-onset schizophrenia. Eur Neuropsychopharmacol 82:57\u201371. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.02.005","journal-title":"Eur Neuropsychopharmacol"},{"key":"2623_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.schres.2024.02.035","volume":"268","author":"B O\u2019Donoghue","year":"2024","unstructured":"O\u2019Donoghue B, Piacenza F, Plapp H, Siskind D, Lyne J (2024) Response rates to sequential trials of antipsychotic medications according to algorithms or treatment guidelines in psychotic disorders. A systematic review and meta- analysis. Schizophr Res 268:193\u2013204. https:\/\/doi.org\/10.1016\/j.schres.2024.02.035","journal-title":"Schizophr Res"},{"key":"2623_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/104454604773840490","volume":"14","author":"R Kant","year":"2004","unstructured":"Kant R, Chalansani R, Chengappa KN, Dieringer MF (2004) The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder. J Child Adolesc Psychopharmacol 14:57\u201363. https:\/\/doi.org\/10.1089\/104454604773840490","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2623_CR30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/02698811241241384","volume":"38","author":"ALST da Rosa","year":"2024","unstructured":"da Rosa ALST, Bezerra OS, Rohde LA, Graeff-Martins AS (2024) Exploring clozapine use in severe psychiatric symptoms associated with autism spectrum disorder: a scoping review. J Psychopharmacol 38:324\u2013343. https:\/\/doi.org\/10.1177\/02698811241241384","journal-title":"J Psychopharmacol"},{"key":"2623_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/JCP.0000000000001816","volume":"44","author":"MA Colijn","year":"2024","unstructured":"Colijn MA (2024) Clozapine use in 22q11.2 deletion syndrome: a systematic review of the literature. J Clin Psychopharmacol 44:168\u2013178. https:\/\/doi.org\/10.1097\/JCP.0000000000001816","journal-title":"J Clin Psychopharmacol"},{"key":"2623_CR32","doi-asserted-by":"publisher","unstructured":"Pimenta de Figueiredo T, de Almeida IR, de Freitas FAC et al (2024) Beyond the off-label: a systematic review of what we know about clozapine use for children. J Child Adolesc Psychopharmacol 2024 Sep 30 Epub ahead of print. https:\/\/doi.org\/10.1089\/cap.2024.0070","DOI":"10.1089\/cap.2024.0070"},{"key":"2623_CR33","doi-asserted-by":"publisher","unstructured":"Verdoux H, Quiles C, de Leon J (2024) Clozapine for persons with neurodevelopmental disorders: a systematic review and expert recommendations for clinical practice. Exp Rev Clin Pharmacol 1\u201311 Advance online publication. https:\/\/doi.org\/10.1080\/17512433.2024.2410395","DOI":"10.1080\/17512433.2024.2410395"},{"key":"2623_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1089\/cap.2018.0036","volume":"28","author":"LM Steinauer","year":"2018","unstructured":"Steinauer LM, Leung JG, Burkey BW et al (2018) A retrospective multicenter evaluation of clozapine use in pediatric patients admitted for acute psychiatric hospitalization. J Child Adolesc Psychopharmacol 28:615\u2013619. https:\/\/doi.org\/10.1089\/cap.2018.0036","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2623_CR35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/00004583-199406000-00005","volume":"33","author":"KE Towbin","year":"1994","unstructured":"Towbin KE, Dykens EM, Pugliese RG (1994) Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome. J Am Acad Child Adolesc Psychiatry 33:651\u2013657. https:\/\/doi.org\/10.1097\/00004583-199406000-00005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2623_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.euroneuro.2015.02.003","volume":"25","author":"C Schneider","year":"2015","unstructured":"Schneider C, Papachristou E, Wimberley T et al (2015) Clozapine use in childhood and adolescent schizophrenia: a nationwide population-based study. Eur Neuropsychopharmacol 25:857\u2013863. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.02.003","journal-title":"Eur Neuropsychopharmacol"},{"key":"2623_CR37","doi-asserted-by":"publisher","unstructured":"Burak Baykara H, Al\u015fen G\u00fcney S, Avcil S (2024) et l, Safety of atypical antipsychotics in a child and adolescent inpatient setting: a naturalistic study. Psychiatry Clin Psychopharmacol 34:109\u2013118. https:\/\/doi.org\/10.5152\/pcp.2024.23726","DOI":"10.5152\/pcp.2024.23726"},{"key":"2623_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/cap.2021.0092","volume":"32","author":"M Adnan","year":"2022","unstructured":"Adnan M, Motiwala F, Trivedi C, Sultana T, Mansuri Z, Jain S (2022) Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis. J Child Adolesc Psychopharmacol 32:2\u201311. https:\/\/doi.org\/10.1089\/cap.2021.0092","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2623_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2013.08.001","volume":"29","author":"C Schneider","year":"2014","unstructured":"Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S (2014) Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 29:1\u201310. https:\/\/doi.org\/10.1016\/j.eurpsy.2013.08.001","journal-title":"Eur Psychiatry"},{"key":"2623_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1089\/cap.2011.0136","volume":"23","author":"KN Maher","year":"2013","unstructured":"Maher KN, Tan M, Tossell JW, Weisinger B, Gochman P, Miller R et al (2013) Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 23:110\u2013116. https:\/\/doi.org\/10.1089\/cap.2011.0136","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2623_CR41","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1097\/01.chi.0000171904.23947.54","volume":"44","author":"G Gerbino-Rosen","year":"2005","unstructured":"Gerbino-Rosen G, Roofeh D, Tompkins DA et al (2005) Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 44:1024\u20131031. https:\/\/doi.org\/10.1097\/01.chi.0000171904.23947.54","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2623_CR42","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/17425255.2022.2160318","volume":"18","author":"C De Las Cuevas","year":"2022","unstructured":"De Las Cuevas C, Arrojo-Romero M, Ruan CJ, Schoretsanitis G, Sanz EJ, de Leon J (2022) Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review. Expert Opin Drug Metab Toxicol 18:715\u2013727. https:\/\/doi.org\/10.1080\/17425255.2022.2160318","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2623_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/JCP.0000000000001843","volume":"44","author":"J de Leon","year":"2024","unstructured":"de Leon J (2024) Can slow personalized titration using c-reactive protein monitoring decrease the high rates and mortality of clozapine-associated myocarditis seen in some countries? A call for research. J Clin Psychopharmacol 44:212\u2013219. https:\/\/doi.org\/10.1097\/JCP.0000000000001843","journal-title":"J Clin Psychopharmacol"},{"key":"2623_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-1625-6388","volume":"55","author":"J de Leon","year":"2022","unstructured":"de Leon J, Schoretsanitis G, Smith RL et al (2022) An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry 55:73\u201386. https:\/\/doi.org\/10.1055\/a-1625-6388","journal-title":"Pharmacopsychiatry"},{"key":"2623_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2023.10.027","volume":"268","author":"R de Filippis","year":"2024","unstructured":"de Filippis R, De Las Cuevas C, Sanz EJ, Schoretsanitis G, Correll CU, de Leon J (2024) Clozapine-associated pericarditis and pancreatitis in children and adolescents: a systematic literature review and pharmacovigilance study using the VigiBase database. Schizophr Res 268:18\u2013130. https:\/\/doi.org\/10.1016\/j.schres.2023.10.027","journal-title":"Schizophr Res"},{"key":"2623_CR46","doi-asserted-by":"publisher","first-page":"759","DOI":"10.4088\/jcp.v69n0509","volume":"69","author":"SE Palmer","year":"2008","unstructured":"Palmer SE, McLean RM, Elli PM, Harrison-Woolrych M (2008) Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 69:759\u2013768. https:\/\/doi.org\/10.4088\/jcp.v69n0509","journal-title":"J Clin Psychiatry"},{"key":"2623_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17512433.2022.2032659","volume":"15","author":"C De Las Cuevas","year":"2022","unstructured":"De Las Cuevas C, Sanz EJ, Rohde C, de Leon J (2022) Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase. Exp Rev Clin Pharmacol 15:65\u201378. https:\/\/doi.org\/10.1080\/17512433.2022.2032659","journal-title":"Exp Rev Clin Pharmacol"},{"key":"2623_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A (2013) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22:57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604","journal-title":"Stat Methods Med Res"},{"key":"2623_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/JCP.0000000000001678","volume":"43","author":"J de Leon","year":"2023","unstructured":"de Leon J, Arrojo-Romero M, Verdoux H et al (2023) Escaping the long shadow cast by agranulocytosis: reflections on clozapine pharmacovigilance focused on the United Kingdom. J Clin Psychopharmacol 43:239\u2013245. https:\/\/doi.org\/10.1097\/JCP.0000000000001678","journal-title":"J Clin Psychopharmacol"},{"key":"2623_CR50","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","volume":"42","author":"JG Leung","year":"2022","unstructured":"Leung JG, de Leon J, Frye MA, Singh B, Cotes RO, McElroy SL (2022) The modernization of clozapine: a recapitulation of the past in the United States and the view forward. J Clin Psychopharmacol 42:565\u2013580. https:\/\/doi.org\/10.1097\/JCP.0000000000001606","journal-title":"J Clin Psychopharmacol"},{"key":"2623_CR51","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/s0140-6736(75)90206-8","volume":"2","author":"J Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1975","unstructured":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4 J, Alhava E, Olkinuora M, Palva I (1975) Letter: Clozapine and agranulocytosis. Lancet 2:611. https:\/\/doi.org\/10.1016\/s0140-6736(75)90206-8","journal-title":"Lancet"},{"key":"2623_CR52","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-0447.1977.tb00224.x","volume":"56","author":"HA Amsler","year":"1977","unstructured":"Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P (1977) Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 56:241\u2013248. https:\/\/doi.org\/10.1111\/j.1600-0447.1977.tb00224.x","journal-title":"Acta Psychiatr Scand"},{"key":"2623_CR53","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1017\/S204579602200066X","volume":"31","author":"E Oloyede","year":"2022","unstructured":"Oloyede E, Blackman G, Whiskey E et al (2022) Clozapine haematological monitoring for neutropenia: a global perspective. Epidemiol Psychiatr Sci 31:e83. https:\/\/doi.org\/10.1017\/S204579602200066X","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2623_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.schres.2023.09.020","volume":"268","author":"O Kirilochev","year":"2024","unstructured":"Kirilochev O, Chumakov E, Kuzo N, Schoretsanitis G (2024) A scoping review of literature on clozapine from former USSR states published in Russian language. Schizophr Res 268:38\u201347. https:\/\/doi.org\/10.1016\/j.schres.2023.09.020","journal-title":"Schizophr Res"},{"key":"2623_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.schres.2023.10.040","volume":"268","author":"N Kuzo","year":"2024","unstructured":"Kuzo N, Blyzniuk B, Chumakov E, Seifritz E, de Leon J, Schoretsanitis G (2024) Clozapine research standards in former USSR states: a systematic review of quality issues with recommendations for future harmonization with modern research standards. Schizophr Res 268:48\u201352. https:\/\/doi.org\/10.1016\/j.schres.2023.10.040","journal-title":"Schizophr Res"},{"key":"2623_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2007-993224","volume":"41","author":"YL Tang","year":"2008","unstructured":"Tang YL, Mao PX, Jiang F et al (2008) Clozapine in China. Pharmacopsychiatry 41:1\u20139. https:\/\/doi.org\/10.1055\/s-2007-993224","journal-title":"Pharmacopsychiatry"},{"key":"2623_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.schres.2023.03.048","volume":"268","author":"CJ Ruan","year":"2024","unstructured":"Ruan CJ, Wang CY, Zang YN et al (2024) A brief history of clozapine in China with a look forward. Schizophr Res 268:25\u201328. https:\/\/doi.org\/10.1016\/j.schres.2023.03.048","journal-title":"Schizophr Res"},{"key":"2623_CR58","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","volume":"11","author":"JM Rubio","year":"2024","unstructured":"Rubio JM, Kane JM, Tanskanen A, Tiihonen J, Taipale H (2024) Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland. Lancet Psychiatry 11:443\u2013450. https:\/\/doi.org\/10.1016\/S2215-0366(24)00097-X","journal-title":"Lancet Psychiatry"},{"key":"2623_CR59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2215-0366(23)00343-7","volume":"11","author":"K Northwood","year":"2024","unstructured":"Northwood K, Myles N, Clark SR et al (2024) Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study. Lancet Psychiatry 11:27\u201335. https:\/\/doi.org\/10.1016\/S2215-0366(23)00343-7","journal-title":"Lancet Psychiatry"},{"key":"2623_CR60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7150\/ijms.10453","volume":"12","author":"G Kimura","year":"2015","unstructured":"Kimura G, Kadoyama K, Brown JB et al (2015) Antipsychotics-associated serious adverse events in children: a analysis of the FAERS database. Int J Med Sci 12:135\u2013140. https:\/\/doi.org\/10.7150\/ijms.10453","journal-title":"Int J Med Sci"},{"key":"2623_CR61","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2013.07.043","volume":"150","author":"M Kiviniemi","year":"2013","unstructured":"Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, H\u00e4kkinen U, Isohanni M, Hakko H (2013) Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res 150:274\u2013280. https:\/\/doi.org\/10.1016\/j.schres.2013.07.043","journal-title":"Schizophr Res"},{"key":"2623_CR62","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41467-023-36973-4","volume":"14","author":"AE Desai Bostr\u00f6m","year":"2023","unstructured":"Desai Bostr\u00f6m AE, Andersson P, Rask-Andersen M, Jarbin H, Lundberg J, Jokinen J (2023) Regional clozapine, ECT and lithium usage inversely associated with excess suicide rates in male adolescents. Nat Commun 14:1281. https:\/\/doi.org\/10.1038\/s41467-023-36973-4","journal-title":"Nat Commun"},{"key":"2623_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17512433.2019.1577134","volume":"12","author":"G Cicala","year":"2019","unstructured":"Cicala G, Barbieri MA, Spina E, de Leon J (2019) A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. Expert Rev Clin Pharmacol 12:219\u2013234. https:\/\/doi.org\/10.1080\/17512433.2019.1577134","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2623_CR64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/17425255.2023.2192401","volume":"19","author":"C De Las Cuevas","year":"2023","unstructured":"De Las Cuevas C, Sanz EJ, Villasante-Tezanos AG, de Leon J (2023) Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase. Expert Opin Drug Metab Toxicol 19:57\u201374. https:\/\/doi.org\/10.1080\/17425255.2023.2192401","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2623_CR65","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/17425255.2024.2373111","volume":"20","author":"J de Leon","year":"2024","unstructured":"de Leon J, Ruan CJ, Schoretsanitis G et al (2024) Investigating in VigiBase\u00ae over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia. Expert Opin Drug Metab Toxicol 20:857\u2013871. https:\/\/doi.org\/10.1080\/17425255.2024.2373111","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2623_CR66","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2023.09.029","volume":"268","author":"N Kang","year":"2024","unstructured":"Kang N, Kim SH, Kim J et al (2024) Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital. Schizophr Res 268:107\u2013113. https:\/\/doi.org\/10.1016\/j.schres.2023.09.029","journal-title":"Schizophr Res"},{"key":"2623_CR67","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1176\/appi.ajp.20230744","volume":"181","author":"JJ Partanen","year":"2024","unstructured":"Partanen JJ, H\u00e4pp\u00f6l\u00e4 P, K\u00e4mpe A et al (2024) High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a Finnish 25-year follow-up register study. Am J Psychiatry 181:879\u2013892. https:\/\/doi.org\/10.1176\/appi.ajp.20230744","journal-title":"Am J Psychiatry"},{"key":"2623_CR68","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/17512433.2021.1877135","volume":"14","author":"G Schoretsanitis","year":"2021","unstructured":"Schoretsanitis G, Ruan CJ, Rohde C, Verdoux H, De Las Cuevas C, Spina E, de Leon J (2021) An update on the complex relationship between clozapine and pneumonia. Expert Rev Clin Pharmacol 14:145\u2013149. https:\/\/doi.org\/10.1080\/17512433.2021.1877135","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2623_CR69","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2215-0366(24)00223-2","volume":"11","author":"V Nersesjan","year":"2024","unstructured":"Nersesjan V, Christensen RHB, Andersen EW, Kondziella D, Benros ME (2024) Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders during the COVID-19 pandemic: a Danish nationwide registry study. Lancet Psychiatry 11:796\u2013806. https:\/\/doi.org\/10.1016\/S2215-0366(24)00223-2","journal-title":"Lancet Psychiatry"},{"key":"2623_CR70","doi-asserted-by":"publisher","unstructured":"Ronaldson A, Nascimento Santana I et al (2024) Severe mental illness and infectious disease mortality: a systematic review and meta-analysis. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102867. EClinicalMedicine 2024:102867","DOI":"10.1016\/j.eclinm.2024.102867"},{"key":"2623_CR71","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/acps.13184","volume":"142","author":"AG Villasante-Tezanos","year":"2020","unstructured":"Villasante-Tezanos AG, Rohde C, Nielsen J, de Leon J (2020) Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia. Acta Psychiatr Scand 142:66\u201367. https:\/\/doi.org\/10.1111\/acps.13184","journal-title":"Acta Psychiatr Scand"},{"key":"2623_CR72","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/JCP.0b013e3182549259","volume":"32","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C (2012) Adverse effects of second-generation antipsychotics in children and adolescents: a bayesian meta-analysis. J Clin Psychopharmacol 32:309\u2013316. https:\/\/doi.org\/10.1097\/JCP.0b013e3182549259","journal-title":"J Clin Psychopharmacol"},{"key":"2623_CR73","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1089\/cap.2011.0134","volume":"22","author":"K Star","year":"2012","unstructured":"Star K, Iessa N, Almandil NB et al (2012) Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis. J Child Adolesc Psychopharmacol 22:440\u2013451. https:\/\/doi.org\/10.1089\/cap.2011.0134","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2623_CR74","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/FTD.0000000000001154","volume":"46","author":"S Jim\u00e9nez-Fern\u00e1ndez","year":"2024","unstructured":"Jim\u00e9nez-Fern\u00e1ndez S, Gurpegui M, Correll CU, de Leon J, Schoretsanitis G (2024) A systematic review of clozapine concentration-dose ratio from therapeutic drug monitoring studies in children and adolescents treated with clozapine for mental disorders. Ther Drug Monit 46:170\u2013180. https:\/\/doi.org\/10.1097\/FTD.0000000000001154","journal-title":"Ther Drug Monit"},{"key":"2623_CR75","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","volume":"12","author":"G Schoretsanitis","year":"2019","unstructured":"Schoretsanitis G, Kane JM, Ruan CJ, Spina E, Hiemke C, de Leon J (2019) A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol 12:603\u2013621. https:\/\/doi.org\/10.1080\/17512433.2019.1617695","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2623_CR76","first-page":"153","volume":"24","author":"C Shelton","year":"2022","unstructured":"Shelton C, Ruan CJ, Ertu\u011frul A, Cotes RO, De Leon J (2022) Should we routinely add CRP to clozapine titrations? - learning from three cases. Neuropsychopharmacol Hung 24:153\u2013161. https:\/\/mppt.hu\/magazin\/pdf\/vol24issue4\/v24i4p153.pdf","journal-title":"Neuropsychopharmacol Hung"},{"key":"2623_CR77","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2217\/pgs-2020-0015","volume":"21","author":"CJ Ruan","year":"2020","unstructured":"Ruan CJ, de Leon J (2020) Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine? Pharmacogenomics 21:369\u2013373. https:\/\/doi.org\/10.2217\/pgs-2020-0015","journal-title":"Pharmacogenomics"},{"key":"2623_CR78","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ridd.2005.05.002","volume":"27","author":"M Sabaawi","year":"2006","unstructured":"Sabaawi M, Singh NN, de Leon J (2006) Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil 27:309\u2013336. https:\/\/doi.org\/10.1016\/j.ridd.2005.05.002","journal-title":"Res Dev Disabil"},{"key":"2623_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2024.03.003","volume":"268","author":"J de Leon","year":"2024","unstructured":"de Leon J (2024) Promoting safer and wider worldwide use of clozapine. Schizophr Res 268:1\u20136. https:\/\/doi.org\/10.1016\/j.schres.2024.03.003","journal-title":"Schizophr Res"}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-024-02623-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-024-02623-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-024-02623-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T10:16:47Z","timestamp":1754648207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-024-02623-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2623"],"URL":"https:\/\/doi.org\/10.1007\/s00787-024-02623-3","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed the principles of the Declaration of Helsinki and adhered to stringent data anonymization protocols which eliminated the need for ethics committee approval at the university of the authors who downloaded the files.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}